2022/06/02Megakaryon Corporation initiates first-in-human clinical trial of allogenic human iPSC-derived HLA homozygous platelets (MEG-002).
2021/10/27Notice of Management change
2021/04/26Megakaryon Corporation announces the completion of 30-day review of Clinical trial notification submitted for human iPS cell-derived HLA homozygous platelets (MEG-002).
2020/10/27Notice of Management change
2020/06/22Contract for manufacturing of clinical trial formulations
2020/02/17Megakaryon Raises Yen 2.8 Billion in Series D Financing
2020/02/14Megakaryon Corporation along with the partner companies won the Minister of State for Science and Technology Policy Award at the 2nd Japan Open Innovation contest.